Intensity Therapeutics, Inc., a late-stage biotechnology firm, focuses on discovering and developing proprietary cancer treatments using its non-covalent drug-conjugation technology. This approach is designed to destroy tumors while enhancing the immune system’s ability to recognize cancer. The company has been named a winner at the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and its leading drug candidate, INT230-6.
The company earned a Platinum award in the Innovator in Biotech Solutions category. INT230-6, Intensity’s primary investigational therapy, is intended for direct injection into tumors. It combines two well-established anticancer drugs—cisplatin and vinblastine sulfate—with a diffusion and cell penetration enhancer known as SHAO. This component enables the drugs to spread more effectively throughout tumors and enter cancer cells more efficiently. INT230-6 is currently being developed alongside standard treatment approaches to enhance long-term responses across a range of solid tumor types.
According to co-founder and CEO Lewis H. Bender, the Pinnacle Award recognition highlights the company’s dedication to transforming cancer treatment. He noted that INT230-6 introduces a novel mechanism for inducing cancer cell death, with the potential to shift cancer from an acute, often fatal condition to a manageable chronic disease, even in cases that do not respond to immunotherapy.
The Pinnacle Awards is a respected annual program that honors excellence across multiple industries. It recognizes organizations, products, and individuals that demonstrate significant innovation, creativity, and impact. Each year, candidates are assessed by a panel of industry experts, media professionals, and consultants to ensure that only the most deserving recipients are selected.